ReviewJournal of neurogastroenterology and motility2014
Placebo effect in clinical trial design for irritable bowel syndrome.
Review in Journal of neurogastroenterology and motility, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2022Pooled it
- Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2019Pooled it
- Pooled it
- Trial
- Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.Journal of digestive diseases · 2022Trial
- Prebiotic Galacto-Oligosaccharides Impact Stool Frequency and Fecal Microbiota in Self-Reported Constipated Adults: A Randomized Clinical Trial.Nutrients · 2022Trial
- Written expressive disclosure in adults with irritable bowel syndrome: A randomized controlled trial.Complementary therapies in clinical practice · 2021Trial
- Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.Neurogastroenterology and motility · 2020Trial
- Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial.Journal of digestive diseases · 2019Trial
- Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Trial
- Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial.Journal of gastroenterology · 2017Trial
- Trial
- Outcome measures for irritable bowel syndrome: a scoping review.BMC medical research methodology · 2025Article
- Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Review
- Negative expectations (nocebo phenomenon) in clinical interventions: A scoping review.Journal of education and health promotion · 2024Article
- Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study.Gastroenterology research and practice · 2023Article
- Exploring the role of gut microbiota in advancing personalized medicine.Frontiers in microbiology · 2023Review
- Effects of herbal medicine (Integrative medicine research · 2021Article
- Article
- Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome.Gastroenterology research and practice · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ongoing efforts to improve clinical trial design in irritable bowel syndrome have been hindered by high placebo response rates and ineffective outcome measures. We assessed established strategies to minimize placebo effect as well as the various ap-proaches to placebo effect which can affect trial design. These include genetic markers such as catechol-O-methyltransferase, opioidergic and dopaminergic neurobiologic theory, pre-cebo effect centered on expectancy theory, and side effect unblinding grounded on conditioning theory. We reviewed endpoints used in the study of IBS over the past decade including adequate relief and subjective global relief, emphasizing their weaknesses in fully evaluating the IBS condition, specifically their motility effects based on functional net value and relative benefit-harm based on dropouts due to adverse events. The focus of this review is to highlight ongoing efforts to improve clinical trial design which can lead to better outcomes in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.